ADVERTISEMENT
Advertise

Content

List volumes - List articles in this issue

Review

Systemic Treatment of Severe Atopic Eczema: A Systematic Review

doi: 10.2340/00015555-0207

Abstract:

Systemic immunosuppressive agents are recommended for patients with atopic eczema in whom disease activity cannot be controlled adequately with topical treatments. Guidelines do not give clear advice which agents to prefer. We systematically reviewed clinical trials on systemic treatment for severe atopic eczema to provide evidence-based treatment recommendations. Standardiz­ed literature search, independent standardized assessment of eligibility and data abstraction was performed by 2 reviewers. Twenty-seven studies totalling 979 patients were included. Eleven studies consistently showed effectiveness of cyclosporine. Cyclosporine is recommended as first option for patients with atopic eczema refractory to conventional treatment. Evidence from randomiz­ed controlled trials also exists for interferon-γ and azathioprine. Although frequently used in clinical practice, systemic glucocorticosteroids have not been assessed adequately in studies. Mycophenolate mofetile showed effectiveness in 2 small uncontrolled studies. Intravenous immunoglobulins and infliximab are not recommended based on published data.

Authors:

Jochen Schmitt, Knut Schäkel, Natalie Schmitt and Michael Meurer

References

Related articles

There are no related articles.


Share with your friends





Actions


Abstract

Full text

PDF

Supplementary


There is no supplementary for this article.

Print information


Volume 87, Issue 2

DOI: 10.2340/00015555-0207

Pages: 100-111

View at PubMed